Drug-induced dystonia.
Among 1,152 psychiatric inpatients who received a phenothiazine, a butyrophenone, or a thioxanthene, 116 developed dystonia attributed to one or more of these drugs. The highest frequencies of dystonia occurred among recipients of haloperidol and the long-acting injectable fluphenazines. For all patients at risk, dystonia was more common in men and in younger patients. For chlorpromazine, high doses, male sex, and low age were each positively associated with dystonia.
D000275:Adjustment Disorders / Q000188:drug therapy; D000328:Adult; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use; D002749:Chlorprothixene / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects / Q000627:therapeutic use; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008653:Mesoridazine / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy; D011619:Psychotropic Drugs / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy; D013881:Thioridazine / Q000009:adverse effects / Q000627:therapeutic use; D013888:Thiothixene / Q000009:adverse effects / Q000627:therapeutic use; D014268:Trifluoperazine / Q000009:adverse effects / Q000627:therapeutic use
D011619:Psychotropic Drugs; D014268:Trifluoperazine; D008653:Mesoridazine; D013888:Thiothixene; D002749:Chlorprothixene; D010546:Perphenazine; D006220:Haloperidol; D013881:Thioridazine; D005476:Fluphenazine; D002746:Chlorpromazine